2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies

Table 1 Patients information

Patient ID	Sex	Age	Disease	CD5(%)	SFI
P1	M	74	MCL	96.5	140.05
P2	F	65	CLL	78.3	207.71
P3	F	56	CLL	95.3	323.27
P4	M	73	CD5⁺ B-CLPDs unclassified	71.6	90.44
P5	F	67	CLL	96.5	109.07
P6	M	51	T-ALL	88.9	100.62
P7	F	58	T-ALL	88.4	83.36

F female, M male, MCL mantle cell lymphoma, CLL chronic lymphocytic leukemia, CD5⁺ B-CLPDs unclassified unclassified CD5⁺ B-cell chronic lymphoproliferative disorders, T-ALL T-cell acute lymphoblastic leukemia

ISSN: 1756-8722